Loading...

News List

克罗恩病新药!欧盟批准Skyrizi:首个治疗克罗恩病的特异性IL-23抑制剂!

2022-11-25


克罗恩病新药!欧盟批准Skyrizi:首个治疗克罗恩病的特异性IL-23抑制剂!

艾伯维近日宣布,欧盟委员会已批准新型抗炎药IL-23抑制剂Skyrizi一个新的适应症:将Skyrizi 600mg静脉诱导和360mg皮下维持治疗方案,用于治疗对常规疗法或生物疗法应答不足、失应答或不耐受的中度至重度活动性克罗恩病成人患者。值得一提的是,Skyrizi是欧盟和美国批准的第一种用于治疗CD的特异性IL-23抑制剂。

Pre: HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

Next: New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.